Cryocell International Stock Today
| CCEL Stock | USD 6.58 0.17 2.65% |
PerformanceVery Weak
| Odds Of DistressLow
|
CryoCell International is selling for 6.58 as of the 22nd of March 2025. This is a 2.65 percent increase since the beginning of the trading day. The stock's lowest day price was 6.24. CryoCell International has only a 7 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 21st of January 1997 | Category Healthcare | Classification Health Care |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida. The company has 8.08 M outstanding shares of which 9.45 K shares are currently shorted by private and institutional investors with about 0.97 trading days to cover. More on CryoCell International
Moving together with CryoCell Stock
Moving against CryoCell Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CryoCell Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Co-CEO and Director | Mark Portnoy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, Health Care, Health Care Providers & Services, Medical Care Facilities, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCryoCell International can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CryoCell International's financial leverage. It provides some insight into what part of CryoCell International's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CryoCell International (CCEL) is traded on NYSE MKT Exchange in USA. It is located in 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677 and employs 82 people. CryoCell International is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.18 M. CryoCell International conducts business under Health Care Providers & Services sector and is part of Health Care industry. The entity has 8.08 M outstanding shares of which 9.45 K shares are currently shorted by private and institutional investors with about 0.97 trading days to cover.
CryoCell International currently holds about 2.96 M in cash with 6.01 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35.
Check CryoCell International Probability Of Bankruptcy
Ownership AllocationThe market capitalization of CryoCell International is $53.18 Million. CryoCell International retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check CryoCell Ownership Details
CryoCell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-12-31 | 13.6 K | |
| Ubs Group Ag | 2024-12-31 | 3.1 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 2 K | |
| Tower Research Capital Llc | 2024-12-31 | 1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 601 | |
| Sbi Securities Co Ltd | 2024-12-31 | 105 | |
| Northwestern Mutual Wealth Management Co | 2024-12-31 | 100.0 | |
| Bank Of America Corp | 2024-12-31 | 33.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 11.0 | |
| Hamilton Lane Advisors Llc | 2024-12-31 | 409.7 K | |
| Sfi Advisors, Llc | 2024-12-31 | 165.3 K |
CryoCell International Historical Income Statement
CryoCell Stock Against Markets
CryoCell International Corporate Executives
Elected by the shareholders, the CryoCell International's board of directors comprises two types of representatives: CryoCell International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoCell. The board's role is to monitor CryoCell International's management team and ensure that shareholders' interests are well served. CryoCell International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoCell International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jill Taymans | CFO and VP of Fin. | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Dividend Share 0.25 | Earnings Share 0.05 | Revenue Per Share | Quarterly Revenue Growth 0.019 |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.